Abstract
Amiodarone is widely used in intensive care units for the treatment of a variety of arrhythmias. It is currently the drug of choice for supraventricular tachyarrhythmias in many units because of its combination of efficacy and safety. This review summarises the current state of knowledge regarding the short-term administration of intravenous amiodarone to control arrhythmias in perioperative, coronary care and intensive care patients. It outlines the electrophysiology, haemodynamics, pharmacokinetics and toxicity of the drug. In particular, it examines the recent concerns regarding acute pulmonary toxicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
